TWI891942B - 氘化化合物 - Google Patents
氘化化合物Info
- Publication number
- TWI891942B TWI891942B TW110143066A TW110143066A TWI891942B TW I891942 B TWI891942 B TW I891942B TW 110143066 A TW110143066 A TW 110143066A TW 110143066 A TW110143066 A TW 110143066A TW I891942 B TWI891942 B TW I891942B
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- formula
- pharmaceutically acceptable
- acceptable salt
- dmt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (18)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18/252,949 US12521370B2 (en) | 2020-12-01 | 2021-12-01 | Inhalable formulations |
| EP21816489.5A EP4255421A1 (en) | 2020-12-01 | 2021-12-01 | Inhalable formulations |
| PCT/EP2021/083755 WO2022117640A1 (en) | 2020-12-01 | 2021-12-01 | Inhalable formulations |
| GBGB2119021.0A GB202119021D0 (en) | 2021-11-18 | 2021-12-24 | Injectable and inhalable formulations |
| US18/056,771 US12318477B2 (en) | 2021-11-18 | 2022-11-18 | Injectable and inhalable formulations |
| US18/711,130 US20250032450A1 (en) | 2021-11-18 | 2022-11-18 | Injectable and inhalable formulations |
| KR1020247020007A KR20240110836A (ko) | 2021-11-18 | 2022-11-18 | 주사용 및 흡입용 제제 |
| EP22818741.5A EP4433049A1 (en) | 2021-11-18 | 2022-11-18 | Injectable and inhalable formulations |
| CA3238583A CA3238583A1 (en) | 2021-11-18 | 2022-11-18 | Injectable and inhalable formulations |
| MX2024005955A MX2024005955A (es) | 2021-11-18 | 2022-11-18 | Formulaciones inyectables e inhalables. |
| IL312859A IL312859A (en) | 2021-11-18 | 2022-11-18 | Injectable and inhalable formulations |
| AU2022393234A AU2022393234A1 (en) | 2021-11-18 | 2022-11-18 | Injectable and inhalable formulations |
| PCT/EP2022/082486 WO2023089132A1 (en) | 2021-11-18 | 2022-11-18 | Injectable and inhalable formulations |
| JP2024529536A JP2024540527A (ja) | 2021-11-18 | 2022-11-18 | 注射製剤及び吸入製剤 |
| CL2024001452A CL2024001452A1 (es) | 2021-11-18 | 2024-05-15 | Formulaciones inyectables e inhalables |
| ZA2024/03906A ZA202403906B (en) | 2021-11-18 | 2024-05-20 | Injectable and inhalable formulations |
| CONC2024/0007518A CO2024007518A2 (es) | 2021-11-18 | 2024-06-14 | Formulaciones inyectables e inhalables |
| US19/192,691 US20250262145A1 (en) | 2021-11-18 | 2025-04-29 | Injectable and inhalable formulations |
Applications Claiming Priority (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17/108,938 | 2020-12-01 | ||
| GB2018955.1 | 2020-12-01 | ||
| GBGB2018955.1A GB202018955D0 (en) | 2020-12-01 | 2020-12-01 | Compositions and compounds for bioanalysis |
| US17/108,938 US20220169606A1 (en) | 2020-12-01 | 2020-12-01 | Compositions and compounds for bioanalysis |
| GB2103981.3 | 2021-03-22 | ||
| US17/208,583 | 2021-03-22 | ||
| US17/208,583 US11773062B2 (en) | 2021-03-22 | 2021-03-22 | Deuterated compounds |
| GB2103981.3A GB2605144A (en) | 2021-03-22 | 2021-03-22 | Deuterated compounds |
| WOPCT/EP2021/060750 | 2021-04-23 | ||
| PCT/EP2021/060750 WO2021116503A2 (en) | 2020-06-02 | 2021-04-23 | Deuterated compounds |
| CA3,118,556 | 2021-05-13 | ||
| CA3118556A CA3118556A1 (en) | 2020-06-02 | 2021-05-13 | Therapeutic solid dosage forms |
| PCT/EP2021/062794 WO2021244831A1 (en) | 2020-06-02 | 2021-05-13 | Therapeutic solid dosage forms |
| WOPCT/EP2021/062794 | 2021-05-13 | ||
| GB2106881.2 | 2021-05-13 | ||
| US17/320,155 US12042564B2 (en) | 2020-06-02 | 2021-05-13 | Therapeutic solid dosage forms |
| US17/320,155 | 2021-05-13 | ||
| GB2106881.2A GB2595776B (en) | 2020-06-02 | 2021-05-13 | Therapeutic solid dosage forms |
| PCT/EP2021/082227 WO2022117359A1 (en) | 2020-12-01 | 2021-11-18 | Deuterated or partially deuterated n,n-dimethyltryptamine compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202237565A TW202237565A (zh) | 2022-10-01 |
| TWI891942B true TWI891942B (zh) | 2025-08-01 |
Family
ID=88294961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110143066A TWI891942B (zh) | 2020-12-01 | 2021-11-18 | 氘化化合物 |
Country Status (8)
| Country | Link |
|---|---|
| EP (2) | EP4275753B1 (https=) |
| JP (1) | JP7834754B2 (https=) |
| CN (1) | CN116761599B (https=) |
| AU (1) | AU2021391581A1 (https=) |
| CA (1) | CA3203020A1 (https=) |
| IL (1) | IL303288A (https=) |
| TW (1) | TWI891942B (https=) |
| WO (1) | WO2022117359A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201907871D0 (en) * | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| CN114787363A (zh) | 2019-10-01 | 2022-07-22 | 恩派瑞安神经科学公司 | 对真菌进行遗传工程化以调节色胺表达 |
| JP7422473B2 (ja) | 2019-11-07 | 2024-01-26 | サイビン ユーケー リミテッド | 合成方法 |
| PH12022551981A1 (en) | 2020-02-04 | 2023-10-16 | Mindset Pharma Inc | Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders |
| KR20240096817A (ko) | 2020-05-19 | 2024-06-26 | 사이빈 아이알엘 리미티드 | 중수소화된 트립타민 유도체 및 사용 방법 |
| US12042564B2 (en) | 2020-06-02 | 2024-07-23 | Cybin Uk Ltd | Therapeutic solid dosage forms |
| US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| US12521370B2 (en) | 2020-12-01 | 2026-01-13 | Cybin Uk Ltd | Inhalable formulations |
| US11660289B2 (en) | 2020-12-01 | 2023-05-30 | Small Pharma Ltd. | Deuterated or partially deuterated N,N-dimethyltryptamine compounds |
| US12318477B2 (en) | 2021-11-18 | 2025-06-03 | Cybin Uk Ltd | Injectable and inhalable formulations |
| MX2024005955A (es) * | 2021-11-18 | 2024-06-11 | Cybin Uk Ltd | Formulaciones inyectables e inhalables. |
| EP4457336A4 (en) | 2021-12-31 | 2026-01-14 | Empyrean Neuroscience Inc | ORGANISMS GENETICALLY MODIFIED TO PRODUCE PSYCHOTROPIC ALKALOIDS |
| US20250051279A1 (en) * | 2022-01-14 | 2025-02-13 | Cybin Irl Limited | Tryptamine compositions and methods |
| US12264131B2 (en) * | 2022-08-19 | 2025-04-01 | Beckley Psytech Limited | Pharmaceutically acceptable salts and compositions thereof |
| CN120344243A (zh) | 2022-10-13 | 2025-07-18 | 赛本英国有限公司 | 包含致幻剂的胃肠外制剂的施用方法 |
| EP4618981A1 (en) | 2022-11-17 | 2025-09-24 | Remedi, Inc. | Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use |
| WO2024156713A1 (en) | 2023-01-23 | 2024-08-02 | Cybin Uk Ltd | Treatment of psychiatric or neurological disorders by parenteral administration of a single, effective parenteral dose of a short-acting psychedelic agent |
| AU2024242138A1 (en) | 2023-03-31 | 2025-11-13 | Cybin Uk Ltd | Combination comprising a monoamine antidepressant agent and a short-duration psychedelic agent |
| US12246005B2 (en) | 2023-06-13 | 2025-03-11 | Beckley Psytech Limited | 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations |
| WO2026013174A1 (en) | 2024-07-10 | 2026-01-15 | Cybin Uk Ltd | Pharmaceutical compositions comprising deuterated n,n-dimethyltryptamine |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019081764A1 (en) * | 2017-10-26 | 2019-05-02 | Consejo Superior De Investigaciones Científicas (Csic) | ASSOCIATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND / OR PSYCHIATRIC DISORDERS |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002520353A (ja) * | 1998-07-16 | 2002-07-09 | マサチューセッツ インスティテュート オブ テクノロジー | ストレスの処置のための組成物 |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| PH12022551981A1 (en) * | 2020-02-04 | 2023-10-16 | Mindset Pharma Inc | Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders |
| WO2021234608A1 (en) * | 2020-05-19 | 2021-11-25 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| AU2021204158B2 (en) * | 2020-06-02 | 2023-03-02 | Cybin Uk Ltd | Deuterated compounds |
| EP3902541B1 (en) * | 2020-06-02 | 2022-09-14 | Small Pharma Ltd | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| US11000534B1 (en) * | 2020-10-08 | 2021-05-11 | Lennham Pharmaceuticals, Inc. | Deuterated derivatives of psilocybin and uses thereof |
-
2021
- 2021-11-18 IL IL303288A patent/IL303288A/en unknown
- 2021-11-18 CA CA3203020A patent/CA3203020A1/en active Pending
- 2021-11-18 JP JP2023533243A patent/JP7834754B2/ja active Active
- 2021-11-18 AU AU2021391581A patent/AU2021391581A1/en active Pending
- 2021-11-18 CN CN202180090269.1A patent/CN116761599B/zh active Active
- 2021-11-18 EP EP23198784.3A patent/EP4275753B1/en active Active
- 2021-11-18 WO PCT/EP2021/082227 patent/WO2022117359A1/en not_active Ceased
- 2021-11-18 TW TW110143066A patent/TWI891942B/zh active
- 2021-11-18 EP EP21815486.2A patent/EP4031529B1/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019081764A1 (en) * | 2017-10-26 | 2019-05-02 | Consejo Superior De Investigaciones Científicas (Csic) | ASSOCIATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND / OR PSYCHIATRIC DISORDERS |
Non-Patent Citations (1)
| Title |
|---|
| 期刊 Morris, P. E. et al., Indolealkylamine metabolism: Synthesis of deuterated indolealkylamines as metabolic probes, Journal of Labelled Compounds and Radiopharmaceuticals , 33(6), 1993, 455-465. * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7834754B2 (ja) | 2026-03-24 |
| CA3203020A1 (en) | 2022-06-09 |
| EP4275753B1 (en) | 2026-03-18 |
| JP2023551058A (ja) | 2023-12-06 |
| CN116761599B (zh) | 2025-05-30 |
| EP4031529C0 (en) | 2023-09-27 |
| CN116761599A (zh) | 2023-09-15 |
| EP4275753A2 (en) | 2023-11-15 |
| WO2022117359A1 (en) | 2022-06-09 |
| IL303288A (en) | 2023-07-01 |
| EP4275753A3 (en) | 2023-12-27 |
| AU2021391581A1 (en) | 2023-07-06 |
| EP4031529B1 (en) | 2023-09-27 |
| EP4031529A1 (en) | 2022-07-27 |
| TW202237565A (zh) | 2022-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI891942B (zh) | 氘化化合物 | |
| US12251371B2 (en) | Deuterated or partially deuterated N,N-dimethyltryptamine compounds | |
| EP3873883B1 (en) | Method of synthesis | |
| US11773062B2 (en) | Deuterated compounds | |
| EP4255421A1 (en) | Inhalable formulations | |
| US20220169606A1 (en) | Compositions and compounds for bioanalysis | |
| HK40103232A (en) | Deuterated or partially deuterated n,n-dimethyltryptamine compounds | |
| HK40078818A (en) | Deuterated or partially deuterated n,n-dimethyltryptamine compounds | |
| HK40078818B (en) | Deuterated or partially deuterated n,n-dimethyltryptamine compounds | |
| CN116056763A (zh) | 包含氘代或部分氘代的n,n-二甲基色胺化合物的治疗组合物 | |
| GB2605144A (en) | Deuterated compounds | |
| HK40060666B (en) | Method of synthesis | |
| HK40060666A (en) | Method of synthesis | |
| HK40056359B (en) | Compounds | |
| HK40056359A (en) | Compounds |